These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 16909049)

  • 41. Catechin polyphenols: neurodegeneration and neuroprotection in neurodegenerative diseases.
    Mandel S; Youdim MB
    Free Radic Biol Med; 2004 Aug; 37(3):304-17. PubMed ID: 15223064
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Neuroprotective effect of neurotrophic factors in experimental models of neurodegenerative disorders.
    Alberch J
    Methods Find Exp Clin Pharmacol; 1997; 19 Suppl A():63-4. PubMed ID: 9403862
    [No Abstract]   [Full Text] [Related]  

  • 43. Heteroarylnitrones as drugs for neurodegenerative diseases: synthesis, neuroprotective properties, and free radical scavenger properties.
    Porcal W; Hernández P; González M; Ferreira A; Olea-Azar C; Cerecetto H; Castro A
    J Med Chem; 2008 Oct; 51(19):6150-9. PubMed ID: 18788732
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Using Caenorhabditis elegans models of neurodegenerative disease to identify neuroprotective strategies.
    Kraemer B; Schellenberg GD
    Int Rev Neurobiol; 2007; 77():219-46. PubMed ID: 17178476
    [No Abstract]   [Full Text] [Related]  

  • 45. Advances in Studies on Neurodegenerative Diseases and their Treatments.
    Gupta SP
    Curr Top Med Chem; 2020; 20(13):2379. PubMed ID: 32529971
    [No Abstract]   [Full Text] [Related]  

  • 46. Conclusive Article: Sorting the Good from the Bad: The Different Approaches to Predict Cognitive Properties of New Symptomatic Drug Candidates for Neurodegenerative Diseases in Early Development.
    Deguil J; Auffret A; Schenker E; Aujard F; Lamberty Y; Bartrès-Faz D; Herrero MT; Blin O; Micallef J; Richardson JC; Bordet R
    CNS Neurol Disord Drug Targets; 2016; 15(7):837-8. PubMed ID: 27549168
    [No Abstract]   [Full Text] [Related]  

  • 47. Do glutamatergic agents represent a new class of antidepressant drugs? Part 1.
    Sanacora G
    J Clin Psychiatry; 2009 Oct; 70(10):1473-5. PubMed ID: 19906350
    [No Abstract]   [Full Text] [Related]  

  • 48. Multitarget-directed ligands for neurodegenerative diseases: real opportunity or blurry mirage?
    Benchekroun M; Maramai S
    Future Med Chem; 2019 Feb; 11(4):261-263. PubMed ID: 30763133
    [No Abstract]   [Full Text] [Related]  

  • 49. Experimental neurodegeneration in hippocampus and its phytoremidation.
    Bhatnagar M; Shukla SD; Bhatnagar R
    J Herb Pharmacother; 2005; 5(2):21-30. PubMed ID: 16260407
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Challenges and opportunities in CNS delivery of therapeutics for neurodegenerative diseases.
    Barchet TM; Amiji MM
    Expert Opin Drug Deliv; 2009 Mar; 6(3):211-25. PubMed ID: 19290842
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Modulating self-assembly of amyloidogenic proteins as a therapeutic approach for neurodegenerative diseases: strategies and mechanisms.
    Liu T; Bitan G
    ChemMedChem; 2012 Mar; 7(3):359-74. PubMed ID: 22323134
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases.
    Zheng H; Weiner LM; Bar-Am O; Epsztejn S; Cabantchik ZI; Warshawsky A; Youdim MB; Fridkin M
    Bioorg Med Chem; 2005 Feb; 13(3):773-83. PubMed ID: 15653345
    [TBL] [Abstract][Full Text] [Related]  

  • 53. PPARs: a new target for neuroprotection.
    Bordet R; Gelé P; Duriez P; Fruchart JC
    J Neurol Neurosurg Psychiatry; 2006 Mar; 77(3):285-7. PubMed ID: 16484630
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Editorial (Thematic Issue: Neuroprotective Effects of Li - It is Elementary).
    Hajek T; Young A
    Curr Alzheimer Res; 2016; 13(8):846-7. PubMed ID: 27040138
    [No Abstract]   [Full Text] [Related]  

  • 55. Molecular Hybridization as a Tool in the Design of Multi-target Directed Drug Candidates for Neurodegenerative Diseases.
    Gontijo VS; Viegas FPD; Ortiz CJC; de Freitas Silva M; Damasio CM; Rosa MC; Campos TG; Couto DS; Tranches Dias KS; Viegas C
    Curr Neuropharmacol; 2020; 18(5):348-407. PubMed ID: 31631821
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Multitarget Therapeutics for Neurodegenerative Diseases.
    Gabr MT; Yahiaoui S
    Biomed Res Int; 2020; 2020():6532827. PubMed ID: 32695817
    [No Abstract]   [Full Text] [Related]  

  • 57. [Protection of nerve cells with drugs. The Institute for Pharmacology and Toxicology in the Pharmacy Department of Philipps University Marburg].
    Schwarz S
    Med Monatsschr Pharm; 2002 Jul; 25(7):226-8. PubMed ID: 12148234
    [No Abstract]   [Full Text] [Related]  

  • 58. Society for Neuroscience--34th annual meeting. Neurodegenerative disease and ion channel modulators. 23-27 October 2004, San Diego, CA, USA.
    Mackonochie M; Phillips T
    IDrugs; 2004 Dec; 7(12):1070-3. PubMed ID: 15599795
    [No Abstract]   [Full Text] [Related]  

  • 59. Pharmacological Approaches Targeting Brain Cell Survival in the Context of Neurodegeneration and Potential Treatment Strategies.
    Aliev G
    Curr Neuropharmacol; 2019; 17(3):198-200. PubMed ID: 30592253
    [No Abstract]   [Full Text] [Related]  

  • 60. Pediatric use of tetracyclines: focus on neurodevelopmental effects.
    Inta I; Hoffmann GF; Bettendorf M
    Pediatr Res; 2017 Nov; 82(5):725-726. PubMed ID: 28700569
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.